LND vs. AVO, FDP, TED, EMH, KAV, ARS, ZNWD, GSP, 1SN, and TUN
Should you be buying Landore Resources stock or one of its competitors? The main competitors of Landore Resources include Advanced Oncotherapy (AVO), FD Technologies (FDP), Ted Baker (TED), European Metals (EMH), Kavango Resources (KAV), Asiamet Resources (ARS), Zinnwald Lithium (ZNWD), Gensource Potash (GSP), First Tin (1SN), and Tungsten West (TUN).
Landore Resources vs. Its Competitors
Landore Resources (LON:LND) and Advanced Oncotherapy (LON:AVO) are both small-cap agriculture companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.
3.2% of Landore Resources shares are owned by institutional investors. Comparatively, 17.8% of Advanced Oncotherapy shares are owned by institutional investors. 39.6% of Landore Resources shares are owned by company insiders. Comparatively, 47.5% of Advanced Oncotherapy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Landore Resources had 3 more articles in the media than Advanced Oncotherapy. MarketBeat recorded 3 mentions for Landore Resources and 0 mentions for Advanced Oncotherapy. Advanced Oncotherapy's average media sentiment score of 0.00 beat Landore Resources' score of -0.33 indicating that Advanced Oncotherapy is being referred to more favorably in the news media.
Landore Resources is trading at a lower price-to-earnings ratio than Advanced Oncotherapy, indicating that it is currently the more affordable of the two stocks.
Advanced Oncotherapy's return on equity of -67.34% beat Landore Resources' return on equity.
Landore Resources has a beta of -0.15, indicating that its stock price is 115% less volatile than the S&P 500. Comparatively, Advanced Oncotherapy has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500.
Summary
Advanced Oncotherapy beats Landore Resources on 7 of the 10 factors compared between the two stocks.
Get Landore Resources News Delivered to You Automatically
Sign up to receive the latest news and ratings for LND and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Landore Resources Competitors List
Related Companies and Tools
This page (LON:LND) was last updated on 7/2/2025 by MarketBeat.com Staff
Free LND Stock Alerts